Evidence map›Paper›PMID 39251830›Full record

ArticleScientific reports2024

Chemosensory assessment and impact on quality of life in neurosensorial cluster of the post COVID 19 syndrome.

Elisa Gentilotti, Anna Gorska, Maria Paola Cecchini, Massimo Mirandola, Marco Meroi, Pasquale De Nardo, Andrea Sartori, Chiara Konishi De Toffoli, Samir Kumar-Singh, Gianluigi Zanusso and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elisa Gentilotti *Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Anna Gorska *Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Maria Paola CecchiniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. mariapaola.cecchini@univr.it.
Massimo MirandolaInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Marco MeroiInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Pasquale De NardoInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Andrea SartoriInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Chiara Konishi De ToffoliInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Samir Kumar-SinghMolecular Pathology Group, Cell Biology & Histology, and Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
Gianluigi ZanussoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Salvatore MonacoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Evelina TacconelliInfectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
ORCHESTRA-UNIVR Study Group

Funding

Horizon 2020 Grant 101016167
6 · The paper itself

Abstract

COVID-19 pandemic brought chemosensory impairment to the forefront of medicine, revealing gaps in the knowledge of pathophysiological mechanisms, true prevalence and preventive/therapeutic alternatives. This is a sub-study of the ORCHESTRA cohort focusing on post-COVID-19 chemosensory symptoms. Risk factors for neurosensorial cluster of post-COVID-19 syndrome (NSc-PCS) were assessed through multivariable analysis. Psychophysical validated tests were applied on a sub-population of 50 patients. Qualitative chemosensory symptoms as well as nasal and oral chemesthesis were evaluated through anamnestic interview and the quality of life through the SF-36 questionnaire. Chemosensory symptoms evolution and olfactory training's outcome were assessed through phone-call interviews. Out of 1187 patients (female, N = 630), 550 (47%) presented NSc-PCS, with a lower risk for older age and monoclonal antibodies treatment, and a higher risk in females (p < 0.001). Out of the 50 patients evaluated with psychophysical tests, 66% showed smell reduction with a qualitative alteration in 50% of hyposmic and 35% of normosmic patients. Hypogeusia was present in 14 (28%) of the patients assessed, with 56% showing a qualitative alteration; 53% of normogeusic patients presented qualitative disorders. NSc-PCS has a complex, fluctuating, multifaceted presentation. Quantifying and characterizing COVID-19-related chemosensory impairment is key to understand underlying mechanisms and to develop preventive and therapeutic treatment.

Indexed as

COVID-19Olfaction DisordersQuality of LifeAdultAgedAnosmiaFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeRisk FactorsSARS-CoV-2SmellSurveys and QuestionnairesChemosensory impairmentPost-COVID syndromeSARS-CoV-2 long-term sequelae

Identifiers

PMID39251830
PMCPMC11384755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.